Home › Vascular Diseases › NCT06510322

Sildenafil to Reduce Vascular Remodeling During Left Ventricular Assist Device Support

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Over 18 years of age
* Supported by a durable LVAD or planned to undergo placement of a durable LVAD
* Be able to give informed consent

Exclusion Criteria:

* History of pre-existing aortic valve prosthesis or an aortic graft
* Allergy to sildenafil
* Taking any nitric oxide (NO) donor medications
* History of complete carotid occlusion

About the study

Contemporary left ventricular assist device (LVAD) therapy improves survival during advanced heart failure but vascular aging develops rapidly leading to major adverse events including stroke and bleeding in nearly half of patients. In this study, the study team aims to investigate whether sildenafil pharmacotherapy, which has anti-fibrotic effects, can reduce vascular aging during LVAD support. An aim of this study is to compare changes in small blood vessels in the gastrointestinal tract between participants receiving sildenafil or placebo. Video capsule endoscopy (VCE) will be used to assess these changes in small blood vessels.

What is being tested

• Sildenafil (drug)
• Placebo (other)

Sponsor: Montefiore Medical Center · Participants: 50 · Started: Mar 12, 2025

Contact the study team

• Omar Saeed, MD · Phone: 718-920-2626
• Lorenzo D'Angelo, MD · Phone: 718-920-2626

Official record on ClinicalTrials.gov — NCT06510322

Locations in the U.S.

Conditions

• Vascular Diseases

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.